Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Multicenter, Multinational, Double-Blind Study to Compare the Pharmacokinetics, Efficacy, Safety and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) Versus Keytruda® in Combination With Chemotherapy for the Treatment of Patients With Advanced Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (BENITO Study)

NCT06687369 is registered in ClinicalTrials.gov with mAbxience Research S.L. as lead sponsor.

NCT NCT06687369
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06687369 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Multicenter, Multinational, Double-Blind Study to Compare the Pharmacokinetics, Efficacy, Safety and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) Versus Keytruda® in Combination With Chemotherapy for the Treatment of Patients With Advanced Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (BENITO Study)
Lead sponsor
mAbxience Research S.L.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 30, 2024
Completion date
September 30, 2027
Enrollment
726 (estimated)
Sites
173

Conditions

As the registry lists them; a condition with its own page is linked.

non squamous non small cell lung cancer